Docket No.: 3493-0179PUS1

Application No.: 10/594,740 Reply dated June 29, 2010

Reply to Office Action of March 29, 2010

Page 2 of 9

AMENDMENTS TO THE CLAIMS

1. - 10. (Cancelled)

- 11. (Currently Amended) A process for the preparation of an aqueous soluble inclusion compound comprising one or more active substances included in one or more host molecules, the active substance or substances not being very soluble in an aqueous medium, wherein it comprises the following successive steps:
- a. bringing one or more active substances into contact with one or more host molecules,
- b. carrying out a step of molecular diffusion by bringing a dense pressurized fluid into contact, in static mode, with the mixture obtained in step (a) in the presence of <u>water as a one or more</u> diffusion agents agent,
- c. depressurizing and recovering the active substance/host molecular complex thus formed,
- d. carrying out a step which consists [[in]] of adding to and mixing with the active substance/host molecule molecular complex an agent for interaction with the complex under atmospheric pressure in a semi-solid medium wherein said agent for interaction with the complex is an acid or a base,
 - e. recovering the aqueous soluble inclusion compound thus formed.
- 12. (Previously Presented) The process as claimed in claim 11, wherein the host molecule is chosen from the group consisting of saccharides or polysaccharides or their mixtures.

13. (Cancelled)

- 14. (Previously Presented) The process as claimed in claim [[13]] 11, wherein the agent for interaction with the complex is an amino acid, a carboxylic acid or aqueous ammonia.
- 15. (Previously Presented) The process as claimed in claim 11, wherein the dense pressurized fluid is carbon dioxide.

Application No.: 10/594,740 Docket No.: 3493-0179PUS1 Page 3 of 9

Reply dated June 29, 2010

Reply to Office Action of March 29, 2010

16. (Previously Presented) The process as claimed in claim 11, wherein the active

substance is a pharmaceutical active principle, a cosmetic active principle or a nutraceutic active

principle.

17. (Previously Presented) The process as claimed in claim 16, wherein the active

substance is chosen from the group consisting of anilides, epipodophyllotoxins, minoxidil,

piroxicam, valeric acid, octanoic acid, lauric acid, stearic acid, tiaprofenic acid, omeprazole,

econazole, miconazole, ketoconazole, astemizole, cyclobenzaprine, nimesulide, ibuprofen,

terfenadine, domperidone, naproxen and eflucimibe.

18. (Previously Presented) The process as claimed in claim 11, wherein the pressure of

the dense fluid is between 0.5 Mpa and 50 MPa and the temperature between 0 and 200°C.

19.(Cancelled)

20. (Previously Presented) The process as claimed in claim 11, wherein step (b) of

molecular diffusion is carried out with stirring.

21. (Currently Amended) The process as claimed in claim 11, wherein the water as the

diffusion agent is added continuously or portionwise in an amount of between 1 and 50% by

weight with respect to the total weight.

22. – 25. (Cancelled)

26. (Previously Presented) The process as claimed in claim 12, wherein the host molecule

is selected from the group consisting of cyclodextrins and their mixture.

27. (New) The process as claimed in claim 11 wherein the agent for interaction is chosen

from the group consisting of acetic acid, tartaric acid, citric acid, gluconic acid, malic acid, lactic

BIRCH, STEWART, KOLASCH & BIRCH, LLP

MAA/MAA/maa

Application No.: 10/594,740 Docket No.: 3493-0179PUS1 Page 4 of 9

Reply dated June 29, 2010 Reply to Office Action of March 29, 2010

acid, maleic acid, fumaric acid, L-lysine, L-valine, L-isoleucine, L-arginine and aqueous

ammonia.